Literature DB >> 28862037

The Relationship Between Osteomyelitis Complication and Drug-Resistant Infection Risk in Diabetic Foot Ulcer: A Meta-analysis.

Yin Chen1, Hui Ding1, Hua Wu1, Hong-Lin Chen1.   

Abstract

In this study, we aimed to investigate the relationship between osteomyelitis complications and drug-resistant infection risk in diabetic foot ulcer. Searches of MEDLINE and ISI databases were performed for the studies. Odds ratios (ORs) for drug-resistant infection incidence were calculated for diabetic foot ulcer patients with or without osteomyelitis complications. Eleven studies (12 cohorts) with 1526 patients were included in this study. Meta-analysis showed that the summary OR was 3.343 (95% CI = 2.355-4.745; Z = 6.75, P < .00001) when compared with osteomyelitis group and without osteomyelitis group. Significant publication bias was found. Sensitivity analysis by only pooled the adjusted ORs showed that the result was robust (the summary OR = 4.081, 95% CI = 2.471-6.739). Subgroup analysis by drug-resistant type showed that the summary OR was 4.391 (95% CI = 2.287-8.394) for methicillin-resistant infection subgroup, and 2.693 (95% CI = 1.882-3.851) for multidrug-resistant infection subgroup. The meta-regression showed that drug-resistant incidence ( t = -0.90, P = .389) and published year ( t = -0.11, P = .913) were not related with the OR changes. In conclusion, our meta-analysis indicates that osteomyelitis complications are related with drug-resistant infection risk in diabetic foot ulcer. We suggest bone culture-based narrow-spectrum antibiotic therapy for osteomyelitis for prevention drug-resistant infection in diabetic foot ulcer.

Entities:  

Keywords:  diabetic foot; drug-resistant infection; meta-analysis; osteomyelitis

Mesh:

Substances:

Year:  2017        PMID: 28862037     DOI: 10.1177/1534734617728642

Source DB:  PubMed          Journal:  Int J Low Extrem Wounds        ISSN: 1534-7346            Impact factor:   2.057


  5 in total

1.  Enhanced Expression of miR-34c in Peripheral Plasma Associated with Diabetic Foot Ulcer in Type 2 Diabetes Patients.

Authors:  Tingting Wu; Dandan Xie; Xiaotong Zhao; Murong Xu; Li Luo; Datong Deng; Mingwei Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-10-15       Impact factor: 3.168

2.  Meta-Analysis: Outcomes of Surgical and Medical Management of Diabetic Foot Osteomyelitis.

Authors:  David H Truong; Roger Bedimo; Matthew Malone; Dane K Wukich; Orhan K Oz; Amanda L Killeen; Lawrence A Lavery
Journal:  Open Forum Infect Dis       Date:  2022-08-09       Impact factor: 4.423

3.  Analysis of risk factors for multidrug-resistant organisms in diabetic foot infection.

Authors:  Xi Yan; Jin-Fang Song; Liang Zhang; Xia Li
Journal:  BMC Endocr Disord       Date:  2022-02-21       Impact factor: 2.763

Review 4.  The Influence of Multidrug-Resistant Bacteria on Clinical Outcomes of Diabetic Foot Ulcers: A Systematic Review.

Authors:  Gianmarco Matta-Gutiérrez; Esther García-Morales; Yolanda García-Álvarez; Francisco Javier Álvaro-Afonso; Raúl Juan Molines-Barroso; José Luis Lázaro-Martínez
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

5.  Topical application of platelet-rich plasma for diabetic foot ulcers: A systematic review.

Authors:  Takashi Hirase; Eric Ruff; Salim Surani; Iqbal Ratnani
Journal:  World J Diabetes       Date:  2018-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.